share_log

Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $8

Benzinga ·  May 9, 2024 00:35

Canaccord Genuity analyst William Plovanic maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $7 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment